Mesenchymal Stem Cells, Osteogenic Lineage and Bone Tissue Engineering: A Review

Kaveh, Kamran; Ibrahim, Rashid; B, Md. Zuki Abu; Ibrah, Tengku Azmi

doi:10.3923/javaa.2011.2317.2330

Cited by 19 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pluripotent or multipotent cell-based therapeutics are vital for skeletal reconstruction in non-healing critical-sized defects [4–6, 59, 60]. A principle challenge is to produce enough regenerative cells through a simple, consistent approach that bypasses ethical concerns and allogeneic immune rejection and avoids genomic alteration for in vivo bone formation.…”

Section: Discussionmentioning

confidence: 99%

“…ESCs do not meet these requirements since ESCs have the potential risk of rejection owing to their allogeneic nature [61] and tumorigenesis [7]. Although MSCs have been proposed as potential cell sources for bone regeneration [59, 60], the low stem cell harvest rate and highly variable multipotency caused by donor variability (particularly in the aged or osteoporotic population, whose MSC number and differentiation capability are considerably reduced) significantly diminish the efficacy of MSC-based therapies [62–64]. In addition, the traditional avenues of MSC derivation, which include bone marrow aspiration, liposuction, and less commonly muscle biopsy, are all more invasive and entail potentially more pain and medical or surgical risks, such as bleeding and anesthesia, than a simple skin biopsy [4–6].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fibromodulin reprogrammed cells: A novel cell source for bone regeneration

Yang

Ting

et al. 2016

Biomaterials

View full text Add to dashboard Cite

Pluripotent or multipotent cell-based therapeutics are vital for skeletal reconstruction in non-healing critical-sized defects since the local endogenous progenitor cells are not often adequate to restore tissue continuity or function. However, currently available cell-based regenerative strategies are hindered by numerous obstacles including inadequate cell availability, painful and invasive cell-harvesting procedures, and tumorigenesis. Previously, we established a novel platform technology for inducing a quiescent stem cell-like stage using only a single extracellular proteoglycan, fibromodulin (FMOD), circumventing gene transduction. In this study, we further purified and significantly increased the reprogramming rate of the yield multipotent FMOD reprogrammed (FReP) cells. We also exposed the ‘molecular blueprint’ of FReP cell osteogenic differentiation by gene profiling. Radiographic analysis showed that implantation of FReP cells into a critical-sized SCID mouse calvarial defect, contributed to the robust osteogenic capability of FReP cells in a challenging clinically relevant traumatic scenario in vivo. The persistence, engraftment, and osteogenesis of transplanted FReP cells without tumorigenesis in vivo were confirmed by histological and immunohistochemical staining. Taken together, we have provided an extended potency, safety, and molecular profile of FReP cell-based bone regeneration. Therefore, FReP cells present a high potential for cellular and gene therapy products for bone regeneration.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Fibromodulin reprogrammed cells: A novel cell source for bone regeneration

Yang

Ting

et al. 2016

Biomaterials

View full text Add to dashboard Cite

show abstract

“…The morphology was analyzed using fluorescent microscopy and scanning electron microscopy (SEM) on the last day of culture. Cell proliferation was assessed using the Alamar Blue assay as described previously [50]. The metabolic activity of the cells was determined after 24, 48, 120 and 168 h of culture.…”

Section: The Influence Of Lipids On the Morphology And Proliferation mentioning

confidence: 99%

The effect of the bioactive sphingolipids S1P and C1P on multipotent stromal cells – new opportunities in regenerative medicine

Marycz

Śmieszek

Jeleń

et al. 2015

Cellular and Molecular Biology Letters

View full text Add to dashboard Cite

Sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) belong to a family of bioactive sphingolipids that act as important extracellular signaling molecules and chemoattractants. This study investigated the influence of S1P and C1P on the morphology, proliferation activity and osteogenic properties of rat multipotent stromal cells derived from bone marrow (BMSCs) and subcutaneous adipose tissue (ASCs). We show that S1P and C1P can influence mesenchymal stem cells (MSCs), each in a different manner. S1P stimulation promoted the formation of cellular aggregates of BMSCs and ASCs, while C1P had an effect on the regular growth pattern and expanded intercellular connections, thereby increasing the proliferative activity. Although osteogenic differentiation of MSCs was enhanced by the addition of S1P, the effectiveness of osteoblast differentiation was more evident in BMSCs, particularly when biochemical and molecular marker levels were considered. The results of the functional osteogenic differentiation assay, which includes an evaluation of the efficiency of extracellular matrix mineralization (SEM-EDX), revealed the formation of numerous mineral aggregates in BMSC cultures stimulated with S1P. Our data demonstrated that in an appropriate combination, the bioactive sphingolipids S1P and C1P may find wide application in regenerative medicine, particularly in bone regeneration with the use of MSCs.

show abstract

“…With vitamin-C present and BGP as phosphate donor the cells were provided with the means to deposit and mineralise extra cellular matrix (ECM) as a measure of the inherent osteogenic capacity of the donor tissue [17].…”

Section: Cell Culturementioning

confidence: 99%